189 related articles for article (PubMed ID: 31370713)
1. A patent review of RAF kinase inhibitors (2010-2018).
Man RJ; Zhang YL; Jiang AQ; Zhu HL
Expert Opin Ther Pat; 2019 Sep; 29(9):675-688. PubMed ID: 31370713
[No Abstract] [Full Text] [Related]
2. Phase I/II RAF kinase inhibitors in cancer therapy.
Turajlic S; Ali Z; Yousaf N; Larkin J
Expert Opin Investig Drugs; 2013 Jun; 22(6):739-49. PubMed ID: 23642225
[TBL] [Abstract][Full Text] [Related]
3. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
4. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling.
Rukhlenko OS; Khorsand F; Krstic A; Rozanc J; Alexopoulos LG; Rauch N; Erickson KE; Hlavacek WS; Posner RG; Gómez-Coca S; Rosta E; Fitzgibbon C; Matallanas D; Rauch J; Kolch W; Kholodenko BN
Cell Syst; 2018 Aug; 7(2):161-179.e14. PubMed ID: 30007540
[TBL] [Abstract][Full Text] [Related]
5. Development of small-molecule inhibitors of Raf.
Wu S; Guo W; Fang B
Recent Pat Antiinfect Drug Discov; 2006 Jun; 1(2):241-6. PubMed ID: 18221149
[TBL] [Abstract][Full Text] [Related]
6. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
Kim DH; Sim T
Arch Pharm Res; 2012 Mar; 35(4):605-15. PubMed ID: 22553052
[TBL] [Abstract][Full Text] [Related]
7. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitors in oncology: a patent review (2015-Present).
Mahapatra DK; Asati V; Bharti SK
Expert Opin Ther Pat; 2017 Aug; 27(8):887-906. PubMed ID: 28594589
[TBL] [Abstract][Full Text] [Related]
9. Targeting Raf-kinase: molecular rationales and translational issues.
Caraglia M; Tassone P; Marra M; Budillon A; Venuta S; Tagliaferri P
Ann Oncol; 2006 Jun; 17 Suppl 7():vii124-7. PubMed ID: 16760274
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the research and development of RAF kinase inhibitors.
Smith RA; Dumas J; Adnane L; Wilhelm SM
Curr Top Med Chem; 2006; 6(11):1071-89. PubMed ID: 16842147
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Raf kinases in human cancer: the Raf dimer dilemma.
Durrant DE; Morrison DK
Br J Cancer; 2018 Jan; 118(1):3-8. PubMed ID: 29235562
[TBL] [Abstract][Full Text] [Related]
12. Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.
Ammar UM; Abdel-Maksoud MS; Oh CH
Eur J Med Chem; 2018 Oct; 158():144-166. PubMed ID: 30216849
[TBL] [Abstract][Full Text] [Related]
13. Raf kinase inhibitors in oncology.
Strumberg D; Seeber S
Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
[TBL] [Abstract][Full Text] [Related]
14. Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.
Martinelli E; Morgillo F; Troiani T; Ciardiello F
Cancer Treat Rev; 2017 Feb; 53():61-69. PubMed ID: 28073102
[TBL] [Abstract][Full Text] [Related]
15. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
Rajakulendran T; Adam DN
Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
[TBL] [Abstract][Full Text] [Related]
16. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
18. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
19. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
20. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
